ClinicalTrials.Veeva

Menu

Fungemia in Hematologic Malignancies

S

Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne

Status

Completed

Conditions

Acute Leukemia
Multiple Myeloma
Chronic Leukemia
Lymphoma

Study type

Observational

Funder types

Other

Identifiers

NCT02451592
SEIFEM 2015

Details and patient eligibility

About

The purpose of this study is to determine the risk factors for fungemia in a population of patients diagnosed with hematologic malignancies and eligible for chemotherapy.

Full description

The coordinating center provides all participating centers with an epidemiologic form, in order to collect data in a comparable way. The requested informations include type of malignancy and its treatment, environmental expositions, laboratory work up, antifungal prophylaxis, clinical signs of infection, microbiological findings, antifungal therapy and outcome of infection at 30 days.

The planned sample size is about 300 patients to be recruited in 35 participating center over 5 years, in a retrospective-prospective fashion. Data check will be performed at the coordinating center. Missing data will be managed to minimize incomplete reports.

Statistical analysis will be performed by an independent reviewer, in order to assess risk factors predictive of fungal infection and outcome.

Enrollment

300 patients

Sex

All

Ages

Under 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients diagnosed with hematologic malignancies and eligible to chemotherapy

Exclusion criteria

  • Patients not eligible to chemotherapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems